Title

CD40L and TNF-alpha Levels After Traumatic Injury

Date

11-8-2021 10:50 AM

Abstract

The biomarkers CD40 ligand and TNF-alpha are proteins that exhibit proinflammatory and prothrombotic effects. A small clinical study has shown that soluble CD40 ligand may have a role in early coagulopathy and inflammatory complications in severely injured patients. It is known that a CD40 ligand increases the production of cytokines such as TNF-alpha, thus, the current study aims to investigate the kinetics of these biomarkers and the extent of upregulation after traumatic injury. Frozen samples collected from baseline, 8, 24, and 48 hours after admission will be used. CD40 ligand and TNF-alpha levels will be quantified using Luminex that will then be compared to various hemostatic laboratory analyses.

Biographies

Queen Revollido, Biochemistry

Queen Revollido is a fourth-year undergraduate student pursuing a bachelor’s degree in biochemistry as a part of the Honors College, BUILD EXITO Program, and McNair Scholars Program. She was introduced to biomedical research during her time at Clark College where she worked with Dr. Roberto Anitori in finding and identifying antibiotic-producing bacteria by genome sequencing. She now works with Dr. Martin Schreiber at the Trauma Research Center at OHSU where she is exploring the upregulation of the proteins CD40 ligand and TNF-alpha after traumatic injury to observe if elevated levels of the proteins can be predictive of worse patient outcomes. The goal of her current study is to better anticipate post-injury complications in order to initiate treatment earlier. During her time as an undergraduate, Queen realized the disparities in science and that sparked her passion in creating a more inclusive scientific community. Queen aims to attend graduate school for biomedical engineering after her time at Portland State University to help advance medical diagnostics and treatments while helping widen inclusivity within academia.

Dr. Martin Schreiber, Faculty Mentor, Chairman of the Trauma Center Association of America

Dr. Martin Schreiber is the Chief of Trauma and the Chief of the Division of Trauma, Critical Care and Acute Care Surgery at Oregon Health & Science University. He is the Chairman of the Trauma Center Association of America. He is a Colonel in the US Army Reserve and has been deployed to Iraq and Afghanistan and he has served as the Joint Theater Trauma System Director. He is an Adjunct Professor of Surgery at the Uniformed Services University of the Health Sciences. Dr. Schreiber is also the director of the Trauma Research Laboratory, the Army Civilian Trauma Training Team and the Donald D. Trunkey Center for Civilian and Combat Casualty Care at OHSU. The Trauma Research Lab has been continuously funded by federal sources since 2001. Lab research interests include prehospital treatment of traumatic brain injury, resuscitation of hemorrhagic shock, hemorrhage control and development of novel blood products. Current funding sources include the Department of Defense, the NIH and private industry. The lab is engaged in over 40 investigational protocols at OHSU. Dr. Schreiber is considered a leader in the trauma community and he has been an invited speaker throughout the United States and around the world.

Disciplines

Biochemistry

Persistent Identifier

https://archives.pdx.edu/ds/psu/36188

This document is currently not available here.

Share

COinS
 
Aug 11th, 10:50 AM

CD40L and TNF-alpha Levels After Traumatic Injury

The biomarkers CD40 ligand and TNF-alpha are proteins that exhibit proinflammatory and prothrombotic effects. A small clinical study has shown that soluble CD40 ligand may have a role in early coagulopathy and inflammatory complications in severely injured patients. It is known that a CD40 ligand increases the production of cytokines such as TNF-alpha, thus, the current study aims to investigate the kinetics of these biomarkers and the extent of upregulation after traumatic injury. Frozen samples collected from baseline, 8, 24, and 48 hours after admission will be used. CD40 ligand and TNF-alpha levels will be quantified using Luminex that will then be compared to various hemostatic laboratory analyses.